The clinicopathological and immunohistochemical characteristics of clinically occult extrapulmonary lymphangioleiomyomatosis in lymph nodes (LN-LAM) being dissected during surgical staging of pelvic malignancy have not been well investigated. We assessed samples from nine female patients (median age, 61). 
Lymphangioleiomyomatosis (LAM) is a rare disorder found in women of reproductive age, mainly affecting the lungs, and potentially with a fatal course due to respiratory failure. [1] [2] [3] [4] Although extrapulmonary LAM is generally regarded as a benign state, a small number of patients are diagnosed as having pulmonary LAM during the long-term follow-up of their extrapulmonary LAM. 2, [5] [6] [7] The lymph node is one of the regions affected by LAM (LN-LAM). Occult lesions are one of the manifestations of LN-LAM, which are incidentally found in dissected lymph nodes during the surgical staging of gynecological and urological malignancies, including uterine, fallopian tube, ovarian or urinary bladder cancer, at an incident rate reported as 1.3%. [8] [9] [10] [11] [12] The reported risk for the development of pulmonary LAM in patients with LN-LAM is controversial. Matsui et al. reported that a diagnosis of LN-LAM preceded the development of pulmonary LAM by 1 to 2 years in 11 of 22 patients with LN-LAM. 5 On the other hand, studies regarding clinically occult LN-LAM have suggested that they are not commonly associated with pulmonary LAM. 9, 10 The difference of the occurrence rate of pulmonary LAM may be because the former included some clinically evident extrapulmonary LAM cases, whereas the latter didn't include those cases. Because pulmonary LAM can be a fatal disease and LN-LAM could be evident or could be determined before the development of lung lesions, it is crucial to understand the biology and diagnosis of LN-LAM. The immunohistochemical characteristics of LN-LAM have been reported in a few small studies, according to which most cases possess smooth muscle markers and express the estrogen receptor (ER). Among melanocytic markers, >95% express HMB45, but the staining pattern is frequently focal and weak. Other melanocytic markers are expressed at lower levels than HMB45, with MiTF present in 86% and MelanA in 17-39% of cases.
9,10
Although cathepsin K is reported as one of the most specific and sensitive markers in pulmonary LAM, it has not been investigated in LN-LAM. 13 Two immunohistochemical markers for LAM have been described recently. One of these, b-catenin, was first described in pulmonary LAM and is also detected in the cytoplasm and membrane of LAM cells in 100% of LN-LAM cases. 10, 14 The other novel marker of LAM is E-cadherin which, to the best of our knowledge, has not been tested in LN-LAM. 15 The primary objective of the present study was to provide information on the detailed distribution of the disease, with clinical correlations and immunohistochemical features in nine patients with clinically occult LN-LAM in the pelvic and para-aortic lymph nodes, and to discuss the follow-up strategy for patients with this distinctive condition.
MATERIALS AND METHODS

Patients and tissue specimens
We identified 10 cases of clinically occult LN-LAM during surgical staging for pelvic malignancy from the pathology archives of Kobe University Hospital, Hyogo Cancer Center and Kobe City Medical Center General Hospital, and through personal communication. LAM had not been indicated in these before surgery. In one case, although occult LN-LAM was found during staging for the uterine cancer, careful retrospective examination of preoperative chest computed tomography (CT) revealed minute pulmonary LAM as previously reported. 16 Therefore, this case was considered pulmonary LAM with LN-LAM and was excluded from the present study. Cases were identified incidentally in specimens from pelvic and para-aortic lymph node dissection for surgical treatment of uterine or ovarian malignant tumors (Cases 1-8), and cystectomy for urinary bladder cancer (Case 9). The clinical findings and follow-up data of all patients were obtained from the patients' files. Family history in Case 9 was not available. Hematoxylin and eosinstained sections for review and formalin-fixed paraffinembedded blocks for immunohistochemistry were available in all nine cases.
Immunohistochemistry
Immunohistochemical staining was performed on representative sections of clinically occult LN-LAM using BenchMark XT (Ventana Medical Systems, Tucson, AZ, USA) according to the manufacturer's instructions. Because they included one to five lesions in each case, a total of 15 lesions were examined using immunohistochemistry. We confirmed comprehensive agreement from all the patients, including those at other participating facilities.
RESULTS
Clinical findings
The clinical findings of the nine patients are summarized in Table 1 . All patients were women, ranging from 44 to 72 years of age (median age 61). Two of the nine patients were at reproductive age, one patient was in a peri-menopausal state, and six were in a natural or surgical postmenopausal state. Although genetic testing for TSC1 and TSC2 mutations was not performed, none of the patients had a past or family history of tuberous sclerosis complex (TSC) or had clinical symptoms associated with pulmonary LAM such as dyspnea on exertion, cough, or hemosputum. Lymphadenopathy caused by LAM was not detected by preoperative CT in any of the cases. Although preoperative chest CT was performed in three cases (Cases 3, 7 and 8), pulmonary LAM was not detected by retrospective careful examination in these cases. Postoperative histological examination revealed that four patients had endometrial endometrioid carcinomas. One patient had the homologous type of endometrial carcinosarcoma (Case 3). Three patients had ovarian high-grade serous carcinomas (Cases 2, 6, and 8), and the remaining patient had urothelial carcinoma (Case 9). Ovarian endometriosis and parametrial endosalpingiosis in Case 1 and adenomyosis in Case 4 were found; they were not adjacent to LAM.
Follow-up data were available for all patients, and the follow-up period varied from 29 to 90 months (median 43). Postoperative chest CT was performed regularly in eight cases; no patient was identified to have pulmonary LAM. Although no periodical chest CT was performed in the remaining one case, the patient displayed no symptoms of pulmonary LAM. Eight of the nine patients were alive without recurrence or metastasis at the time of analysis. Only one patient had died of uterine carcinoma 30 months after surgery (Case 1). Minute pelvic lymph node LAM 31
Histological findings
The number of affected lymph nodes was 1-15 (median, 2.0) in the pelvic or para-aortic LNs. The distribution of lesions is illustrated in Fig. 1 . Four patients had a single lesion and five had multiple lesions. In six cases, clinically occult LN-LAM was observed only within pelvic LNs (Cases 1, 2, 4, 5, 7 and 9). In Cases 3 and 8, lesions were detected only in para-aortic LNs, whereas in Case 6, they were present in both pelvic and para-aortic LNs. Among those patients with multiple clinically occult LN-LAM lesions, 3 of 5 showed laterality in the distribution of the lesions; in Cases 1, 3 and 7, all the clinically occult LN-LAMs were distributed to the right or to the left side. Sizes of clinically occult LN-LAM varied from 1-13 mm (median 3.0 mm). All lesions could only be identified microscopically, and showed similar histology. They were composed of aggregations of epithelioid and myoid cells (LAM cells) confined to lymph nodes and pericapsular adipose tissue. LAM cells were loosely arranged in fascicular, nested and whorl patterns along the subcapsular sinus (Fig. 2a, b) . They had polygonal nuclei with inconspicuous nucleoli and clear to pale eosinophilic cytoplasm. Neither cellular atypia nor mitosis was found in any case. Necrosis was also not found in any cases, however foci of hyalinization were observed. Anastomosing networks of slit-like spaces lined by flattened cells were observed throughout the lesions (Fig. 2c, d ). These slit-like spaces were empty or contained small numbers of lymphocytes or erythrocytes.
The immunohistochemical findings are summarized in Table 2 . The LAM cells of all cases were diffusely positive for a-SMA and focally or diffusely positive for desmin (Fig. 3a) . Although cathepsin K showed cytoplasmic positivity with moderate intensity for all cases, the extent of positive cells were varied (5 to 100%). Staining for HMB45 was focal and weak (Fig. 3b) , and in almost all lesions, only a small number of HMB45-positive LAM cells were found. ER and PgR were positive in all cases with the exception of one that was PgR-negative. The flattened cells lining the slit-like spaces were also positive for D2-40 (Fig. 3d) . The cytoplasm of LAM cells in all cases was diffusely positive for b-catenin and E-cadherin, with occasional strong positivity for the latter in the perinuclear Golgi region (Fig. 3c, e, f) . Figure 1 Schematic of LN-LAM distribution. The outlined characters indicate each LAM lesion/sampled LN which were categorized into six subgroups (supra and inferior para-aortic, common iliac, external iliac, suprainguinal, obturator nodes). In six cases, LN-LAM was observed within pelvic LNs (Cases 1, 2, 4, 5, 7 and 9). In Case 3, lesions were detected in para-aortic LNs. In Case 6, lesions were detected on both sites. In Case 7, although lesions were detected on the left side within the pelvis, they are not illustrated because their exact location was not noted. In Case 2, 5, and 7, multiple lesions were identified on immunohistochemical evaluation. There were no differences in staining patterns between the lesions in the same cases.
DISCUSSION
Clinically occult LN-LAM has been reported as a unique pathological condition in a small number of case studies. Iwasa et al. reported three cases of single or multiple clinically occult LN-LAM in the pelvic and para-aortic lymph nodes in association with uterine cancer. None of the three patients had TSC or LAM in other organs. 11 Rabban et al.
reported 26 patients with single or multiple clinically occult LN-LAM averaging 3.5 mm in size and involving pelvic and para-aortic LNs associated with gynecological and genitourinary malignancy in patients of median age 56 years. Of these, although two patients had TSC and four had uterine LAM, none had pulmonary LAM. 9 Schoolmeester et al.
reported 19 female patients with single or multiple clinically occult LN-LAM at 3-123 months (mean 33.8) follow-up; the mean patient age in that study was also 56, with no history of TSC or pulmonary LAM. One patient with a 25 mm LN-LAM lesion had persistent local nodal LAM, whereas the remaining 18 cases with LN-LAM lesions 1-9 mm (mean 4.3) in size had no evidence of persistent or recurrent nodal LAM. 10 Nagasaka et al. examined 80,677 pelvic and paraaortic LNs in detail from 1,656 patients with gynecological malignancies and identified 21 (1.3% of the total population) with clinically occult LN-LAM. 12 These reports suggest that the biology of clinically occult LN-LAM is unique because of their older onset age, largely stable/slow-progression of disease, and only a tenuous connection with TSC and pulmonary LAM.
As noted, the biology of clinically occult LN-LAM is distinct, and the age of onset is different from that of pulmonary LAM. Although almost all patients with pulmonary LAM are women of reproductive age and there are only a few reports of postmenopausal women with extrapulmonary LAM, 5, 17 in the present study, 8 of 9 patients were peri-or post-menopausal and only one was of late reproductive age (44 years old). This finding is consistent with previous reports. 9-11 LAM is considered to be an estrogendependent lesion and this hormone seems to play a central role in disease progression because of its predilection for young women and the presence of ER and/or PgR in the proliferating cells. 11, 18 Although most patients in this study were considered to have low-or nonfunctioning ovaries, four of nine had uterine endometrioid carcinoma that developed in the setting of excess estrogen relative to progesterone. 19 This relative estrogen excess might affect the development of both primary gynecological malignancy and clinically occult LN-LAM in these cases, whereby detection of the latter may simply depend on age at surgery in patients who may have had unrecognized stable LN-LAM for many years. Therefore, clinically occult LN-LAM could begin to spread under the influence of increased estrogen. Although the origin and pathobiology of LAM remains under investigation, there is an attractive hypothesis of LAM origin. Hayashi et al. reported that 90% of patients with pulmonary LAM had uterine LAM and hypothesized that the uterus or a nearby locale in the retroperitoneum or pelvic cavity may be the primary site where LAM arises and it spreads through lymphatics, and reaches the lung. 7 Clinically occult LN-LAM can involve multiple lymph nodes and interestingly, uterine LAM is found in up to 15% of clinically occult LN-LAM cases. 9 In the present study, we found one corresponding case with LN-LAM associated with uterine LAM, which was diagnosed during staging of the uterine carcinoma. 16 In this case, pulmonary LAM was detected on careful retrospective examination of preoperative chest CT. We excluded this case from the study as it was considered to be pulmonary LAM with lymph node involvement. Although previous studies suggested small clinically occult LN-LAMs are unlikely to be associated with pulmonary LAM lesions, 9-11 it is important to note that systemic LAM can be found following the detection of LN-LAM. 5 Immunohistochemistry is useful for identifying small LN-LAM lesions and differentiating them from alternatives, including smooth muscle proliferative lesions or fibrotic lesions after chemotherapy. In particular, HMB45 is known to be a highly sensitive and specific marker not only for pulmonary LAM but also for LN-LAM.
9,10,20 However, the staining pattern of HMB45 in LAM is often very focal and weak. Therefore, careful observation is needed in order not to overlook the lesion, and it is desirable to have additional markers. Recently, cathepsin K and b-catenin have been reported as markers for LAM. 10, 13, 14 In the present study, all 15 LN-LAM lesions showed positivity for cathepsin K and b-catenin suggesting that they are useful novel markers to assess LN-LAM. However, there are some limitations of these markers. The percentage of the positive tumor cells in cathepsin K was varied by case and in this study, less than 50% of the tumor cells were positive for cathepsin K in more than two thirds of the tested lesions. And its intensity was moderate for all cases. Although b-catenin was diffusely positive in the cytoplasm and on the cell membrane of LAM cells in all the cases studied in the present study, b-catenin-positive non-tumor cells adjacent to the tumor cells, including endothelium, were frequently observed. Therefore, in problematic cases, the distinction between positivity of tumor cells and non-neoplastic cells may be challenging. In addition to b-catenin, we assessed a novel LAM marker, E-cadherin and found diffuse cytoplasmic expression in all cases. 15 E-cadherin distribution is regulated by tuberin encoded by TSC2; loss of TSC2 function is coupled to loss of membrane E-cadherin, which is retained largely in the Golgi. 15 We found some LAM cells that were indeed positive for E-cadherin in the perinuclear Golgi area. To the best of our knowledge, this is the first report to demonstrate the expression of E-cadherin in LN-LAM lesions. Cytoplasmic and perinuclear positivity of Ecadherin may indicate that LN-LAM cells are related to TSC2 mutations, although this remains to be proven. LAM is now classified as one of the PEComa family, which includes not only LAM but also angiomyolipoma, clear cell sugar tumor. LAM consists of myoid spindle cells, which are positive for melanotic marker, and lymphatic canal. The pathological diagnosis of LN-LAM is not usually difficult when typical histological findings are observed. A variety of smooth muscle neoplasm such as intranodal leiomyoma and lymph node involvement of disseminated peritoneal leiomyomatosis and PEComa, particularly angiomyolipoma, can be differential diagnosis. The immunohistochemical staining of melanotic markers are helpful and careful, observation for lymphatic ducts, adipose components and blood vessels may be needed to distinguish LN-LAM from them.
In summary, we have described clinical, histopathologic, and immunohistochemical features of nine cases of pelvic and para-aortic clinically occult LN-LAM associated with pelvic malignant tumors. Clinically occult LN-LAM affected not only premenopausal women but also postmenopausal women unlike pulmonary LAM, which is found only in women of reproductive age. b-catenin, E-cadherin and cathepsin K may be diagnostic makers in addition to HMB45, positivity for which is sometimes difficult to assess. Although most previous reports suggest that clinically occult LN-LAM associated with pelvic malignancy does not affect prognosis, 9-11 because pulmonary LAM was retrospectively found after surgery in one report, 16 careful follow-up or pulmonary examination may be advisable in patients with clinically occult LN-LAM. A limitation of the present study is the small number of cases available. Further investigations are necessary to determine the detailed biology of clinically occult LN-LAM.
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